ABO1105
Phase 2Biologic
ABO1105 is one of 6 biologic programs targeting Respiratory Syncytial Virus. It is currently in Phase 2.
1
Indications
2
Total Trials
2
Active Trials
5
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
9 competitors in Respiratory Syncytial Virus
#DrugCompanyPhaseTrials
1Mrna-1345
ModernaPhase 3
RSV Vaccine 1
SanofiPhase 2
ABO1105
SSuzhou Abogen Biosciences Co., Ltd.
Phase 2
Mrna-1365
ModernaPhase 1
Bivalent RSV Vaccine (IN006)
SShenzhen Shenxin Biotechnology Co., Ltd
Phase 1
Control Vaccine
GSKPreclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for ABO1105. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details